HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Schering-Plough

This article was originally published in The Rose Sheet

Executive Summary

Sun care revenues soared to $21 mil. during the third quarter compared with $3 mil. in the prior year period, benefiting from the "successful launch" of Coppertone Continuous Spray sun care products, company announces in Oct. 24 earnings presentation. Firm launched Continuous Spray earlier this year as the only sunscreen with advanced Airspray technology, releasing product in a mist (1"The Rose Sheet" Feb. 21, 2005, p. 7). Foot care products declined 2% to $85 mil., firm notes. Consumer Health Care sales fell 2% to $235 mil., largely due to lower sales of OTC products, firm notes. Net sales improved 15% to $2.28 bil., while net income to common shareholders more than tripled at $43 mil., compared to $14 mil. last year...

You may also be interested in...



Coppertone Sunscreens, Self Tanning Extensions Unveiled

Schering-Plough is expanding Coppertone anti-aging sun care offerings with the launch of Ultrasheer Sunscreen Faces, the firm said

Biogen Sees Improving Momentum In Slow Leqembi Launch

Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.

Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease

Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS013475

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel